Moderna's Personalized mRNA Cancer Vaccine Breakthrough
Moderna and Merck announce positive Phase 3 results for their personalized mRNA melanoma vaccine. This analysis explores the operational challenges of individualized medicine, the regulatory pathway for process-based approvals, and the strategic expansion into new oncology and autoimmune markets.